DOCSLIB.ORG

Pro Ezgc™ Methods Development Software • GC Optimization Software—Software Routines for Fast GC, Windows® 95, 98, 2000, NT, ME, and XP

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pro Ezgc™ Methods Development Software • GC Optimization Software—Software Routines for Fast GC, Windows® 95, 98, 2000, NT, ME, and XP p711-726.qxd 11/18/2002 12:47 PM Page 711 Chlorinated Pesticide Compounds Retention Time Index Data collected using 30m, 0.53mm ID, 0.50µm Rtx®-5, Rtx®-35, and Rtx®-1701 columns. Oven temp.: Rtx®-5: 100°C (hold 5 min.) to 275°C @ 4°C/min. (hold 6 min.); Rtx®-35: 100°C (hold 5 min.) to 275°C @ 4°C/min. (hold 16 min.); Rtx®-1701: 100°C (hold 5 min.) to 275°C @ 4°C/min. (hold 6 min.); Carrier gas: heli- um; Regulation: constant pressure; Linear velocity: 40.0cm/sec. @ 100°C; Dead time: 1.250 min. @ 100°C. Rtx®-5 Rtx®-35 Rtx®-1701 Rtx®-5 Rtx®-35 Rtx®-1701 Component Name Ret. Time Ret. Time Ret. Time Component Name Ret. Time Ret. Time Ret. Time DBCP 2.103 1.972 2.262 isodrin 17.605 20.569 19.923 hexachlorocyclopentadiene 3.193 3.356 3.418 heptachlor epoxide 18.24 21.352 21.536 tetradecane 3.528 2.633 3.221 captan 18.731 24.41 24.899 γ etridiazole 4.526 6.155 6.279 -chlordane 19.365 22.333 23.161 RETENTION TIME INDEXES chlorneb 5.407 7.847 8.227 endosulfan I 19.958 23.11 22.759 hexadecane 6.955 5.074 6.176 α-chlordane 20.118 23.131 23.472 propachlor 7.589 10.474 12.257 cis-nonachlor 20.341 22.654 23.608 tetrachloro-m-xylene (ISTD) 7.866 9.204 8.911 dieldrin 21.21 24.579 24.521 trifluralin 9.046 9.299 12.877 4,4'-DDE 21.295 24.513 24.03 cis-diallate 9.446 11.925 11.811 docosane 21.519 19.169 20.449 chlorpropham 9.511 10.724 13.229 endrin 22.229 26.179 25.483 α-BHC 9.673 12.784 13.763 nitrofen 22.285 26.446 27.441 trans-diallate 9.822 11.468 12.602 TOK 22.285 26.446 27.409 hexachlorobenzene 10.016 11.886 11.306 ethylan 22.531 26.131 25.292 dichloran 10.268 14.205 16.491 perthane 22.531 26.131 25.292 simazine 10.613 14.727 16.509 endosulfan II 22.695 27.181 27.926 atrazine 10.855 14.525 16.39 chlorobenzilate(a) 22.857 26.139 27.093 β-BHC 11.034 15.413 20.17 chloropropylate 22.878 25.75 26.849 γ-BHC 11.233 14.855 15.869 4,4'-DDD 23.295 27.158 27.862 lindane 11.233 14.855 15.869 trans-nonachlor 23.323 26.64 27.957 PCNB 11.428 14.284 14.418 endrin aldehyde 23.631 28.634 29.981 pronamide 11.776 13.833 17.649 kepone 23.747 26.625 25.26 Environmental Compounds octadecane 11.819 9.444 10.826 carbophenothion 24.486 28.606 28.705 dichlone 12.141 16.428 16.979 endosulfan sulfate 24.741 29.434 31.535 δ-BHC 12.433 17.207 21.072 4,4'-DDT 25.01 28.607 28.563 chlorothalonil 12.66 16.963 19.6 tetracosane 25.837 23.576 24.785 terbacil 12.767 17.497 21.225 captafol 25.933 31.856 32.7 metribuzin 14.154 18.973 19.872 endrin ketone 26.871 33.133 33.156 heptachlor 14.613 16.842 16.686 methoxychlor 27.792 32.464 31.57 alachlor 14.795 17.919 19.272 dibutylchlorendate 29.181 31.458 31.869 aldrin 16.247 18.461 17.936 mirex 29.273 32.799 30.193 metolachlor 16.547 19.571 20.95 hexacosane 29.84 27.532 28.793 eicosane 16.829 14.396 15.758 fenarimol 30.301 35.227 35.243 dicofol 16.851 20.574 20.758 rubigan 30.301 34.954 35.568 kelthane 16.851 20.574 20.758 cis-permethrin 31.912 35.558 34.886 bayleton 17.028 19.949 22.288 trans-permethrin 32.248 36.25 35.254 triadimefon 17.028 19.949 22.288 decachlorobiphenyl (ISTD) 35.131 38.949 36.977 dacthal 17.03 19.999 20.738 octacosane — 31.28 32.61 DCPA 17.03 19.999 20.738 Pro ezGC™ Methods Development Software • GC optimization software—software routines for Fast GC, Windows® 95, 98, 2000, NT, ME, and XP. • Optimize temperature and flow programs from a single analysis. • Reduce analyses times and improve sample resolution. • Model retention gap and guard column applications, including Restek Integra-Guard™ columns. • Model columns in parallel or in series for process GC and multi-dimensional GC analyses. • Optimize dual-column run conditions. • Low price. Includes the FREE Master Library which contains over 3,000 compounds! Pro ezGC™ includes the entire Master Set of Retention Index Libraries at no extra charge! These libraries contain more than 3,000 compounds analyzed on the most commonly used stationary phases, in ten different application areas including: pesticides, PCBs, dioxins/furans, flavor and fragrance compounds, drugs of abuse, FAMEs, semi- volatile and volatile pollutants, petroleum hydrocarbons, and solvents and chemicals. These libraries permit comput- er simulation without entering actual laboratory data. Order by phone 800-356-1688 or 814-353-1300 • Order online www.superchrom.it p711-726.qxd 11/15/2002 8:29 AM Page 712 Chlorinated Pesticide Compounds Retention Time Index Data collected using 30m, 0.32mm ID, 0.50µm Rtx®-CLPesticides and Rtx®-CLPesticides2 columns. Oven temp.: 120°C (hold 1 min.) to 300°C @ 9°C/min.; Carrier gas: helium; Flow rate: 1.31mL/min. @ 120°C; Linear velocity: 27.62cm/sec.; Dead time: 1.810 min.; Regulation: constant pressure. Rtx®-CLPesticides Rtx®-CLPesticides2 Rtx®-CLPesticides Rtx®-CLPesticides2 Component Name Ret. Time Ret. Time Component Name Ret. Time Ret. Time chloroform 1.825 1.837 atrazine 12.184 14.491 bromodichloromethane 1.851 1.896 terbuthylazine 12.576 14.846 chlorodibromomethane 1.900 2.049 secbumeton 12.659 15.158 1,1,1,2-tetrachloroethane 2.000 2.178 isodrin 12.881 16.819 bromoform 2.054 2.688 simetryn 12.907 16.436 1,2-dibromoethane 2.071 2.075 ametryn 12.987 16.457 1,2,3-trichloropropane 2.217 2.558 pentachloronitrobenzene 13.106 14.877 DBCP 2.443 3.567 3,4-dinitrotoluene 13.221 13.637 hexachlorocyclopentadiene 4.321 6.421 heptachlor epoxide (B) 13.368 16.743 4-chloro-3-nitrobenzotrifluoride 6.020 5.826 γ-chlordane 13.652 17.181 1-bromo-2-nitrobenzene 8.049 9.037 prometryn 13.840 16.473 hexachlorobenzene 8.913 12.430 α-chlordane 13.946 17.522 diallate (cis/trans) 9.077 12.162 terbutryn 14.157 16.762 α-BHC 9.239 12.426 4,4'-DDE 14.179 17.848 diallate (cis/trans) 9.452 12.492 endosulfan I 14.215 17.673 γ-BHC 10.064 13.409 dieldrin 14.743 18.292 β-BHC 10.321 12.426 endrin 15.236 18.940 δ-BHC 10.751 14.386 4,4'-DDD 15.449 19.133 1,2-dinitrobenzene 11.216 11.937 chlorobenzilate 15.657 19.339 heptachlor 11.260 14.559 endosulfan II 15.719 19.412 RETENTION TIME INDEXES prometon 11.380 14.110 4,4'-DDT 16.009 19.832 simazine 11.503 14.463 endrin aldehyde 16.601 20.182 atraton 11.691 14.064 methoxychlor 17.105 21.264 propazine 11.819 14.551 endosulfan sulfate 17.495 20.786 aldrin 11.962 15.381 endrin ketone 18.081 22.054 tributylphosphate 12.074 12.655 triphenylphosphate 20.111 26.284 Nitrogen-Containing Pesticide Compounds Retention Time Index Data collected using 30m, 0.53mm ID, 0.50µm Rtx®-5, Rtx®-35, and Rtx®-1701 columns. Oven temp.: Rtx®-5: 150°C (hold 5 min.) to 275°C @ 4°C/min. (hold 3 min.); Rtx®-35: 150°C (hold 5 min.) to 275°C @ 4°C/min. (hold 7 min.); Rtx®-1701: 150°C (hold 5 min.) to 275°C @ 4°C/min. (hold 5 min.); Carrier gas: helium; Regulation: constant pressure; Linear velocity: 40.0cm/sec. @ 150°C; Dead time: 1.250 min. @ 150°C. Rtx®-5 Rtx®-35 Rtx®-1701 Rtx®-5 Rtx®-35 Rtx®-1701 Component Name Ret. Time Ret. Time Ret. Time Component Name Ret. Time Ret. Time Ret. Time 1,3-dimethyl-2-nitrobenzene 6.12 8.975 — alachlor 27.742 31.069 32.362 dodecane 6.137 4.733 5.187 ametryn 27.842 32.084 32.592 Environmental Compounds dichlorvos 7.795 11.342 12.865 prometryn 28.112 31.828 32.397 EPTC 11.145 13.408 13.83 terbutryn 28.699 32.547 33.075 tetradecane 12.396 10.615 11.704 bromacil 29.283 34.755 38.462 butylate 13.545 14.955 15.678 metolachlor 29.602 32.72 34.082 mevinphos-cis 13.764 18.046 19.697 eicosane 29.907 27.478 28.82 vernolate 14.098 16.133 16.51 triadimefon 30.043 33.08 35.4 pebulate 14.57 16.704 17.035 MGK 264A 30.628 33.376 33.994 tebuthiuron 16.505 21.271 24.066 diphenamid 30.797 36.102 36.418 molinate 16.894 20.619 20.056 isopropalin 31.033 33.532 35.299 hexadecane 18.886 16.7 17.76 MGK 264B 31.204 34.492 — propachlor 19.424 23.206 25.016 pendamethalin 31.508 34.731 35.717 cycloate 19.967 22.63 22.559 merphos 31.557 33.359 33.221 ethoprop 20.068 23.485 24.267 stirofos 33.307 37.568 38.174 chlorpropham 20.672 23.485 26.19 butachlor 33.528 35.997 37.334 trifluralin 21.643 22.128 25.822 napropamide 33.812 38.105 38.706 benefin 21.767 22.311 25.964 fenamiphos 33.925 38.216 39.476 atraton 23.021 26.937 27.89 tricyclozole 34.198 41.331 43.369 prometon 23.368 26.99 27.861 docosane 34.638 32.233 33.558 atrazine 23.552 27.537 29.448 carboxin 34.808 40.365 40.676 propazine 23.801 27.298 29.293 oxadiazon 34.819 37.477 39.076 terbufos 24.195 26.986 27.756 oxyfluorfen 35.133 37.958 40.832 pronamide 24.484 26.902 30.725 norflurazon 38.168 43.291 46.651 profluralin 24.645 25.286 28.781 hexazinone 38.718 45.075 46.735 octadecane 24.678 22.229 23.596 tetracosane 38.955 36.632 37.9 disulfoton 25.057 28.498 29.119 triphenyl phosphate (ISTD) 39.126 43.949 43.959 Diazinon® 25.058 27.932 28.198 hexacosane 42.905 40.716 41.871 terbacil 25.654 30.658 34.349 fenarimol 43.358 48.382 49.362 metribuzin 27.074 32.106 32.976 octacosane 46.548 44.339 45.678 bimetryn 27.615 32.215 32.743 fluridone 48.914 58.305 — Order by phone 800-356-1688 or 814-353-1300 • Order online www.superchrom.it p711-726.qxd 11/15/2002 8:29 AM Page 713 Organophosphorus Pesticide Compounds Retention Time Index Data collected using 30m, 0.32mm ID, 0.50µm Rtx®-OPP column and 30m, 0.32mm ID, 0.32µm Rtx®-OPP2 column.
Load more

Recommended publications
  • DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent A
    DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent Alcoholism: Recognizing, Intervening, and Treating Series No. 6. INSTITUTION Ohio State Univ., Columbus. Dept. of Family Medicine. SPONS AGENCY Health Resources and Services Administration (DHHS/PHS), Rockville, MD. Bureau of Health Professions. PUB DATE 87 CONTRACT 240-83-0094 NOTE 30p.; For other guides in this series, see CG 021 187-193. AVAILABLE FROMDepartment of Family Medicine, The Ohio State University, Columbus, OH 43210 ($5.00 each, set of seven, $25.00; audiocassette of series, $15.00; set of four videotapes keyed to guides, $165.00 half-inch tape, $225.00 three-quarter inch tape; all orders prepaid). PUB TYPE Guides - Classroom Use - Materials (For Learner) (051) -- Reports - General (140) EDRS PRICE MF01 Plus Plstage. PC Not Available from EDRS. DESCRIPTORS *Adolescents; *Alcoholism; *Clinical Diagnosis; *Drug Use; *Family Problems; Physician Patient Relationship; *Physicians; Substance Abuse; Units of Study ABSTRACT This document is one of seven publications contained in a series of materials for physicians on recognizing, intervening with, and treating adolescent alcoholism. The materials in this unit of study are designed to help the physician know the different classes of drugs, recognize common presenting symptoms of drug overdose, and place use and abuse in context. To do this, drug characteristics and pathophysiological and psychological effects of drugs are examined as they relate to administration,
    [Show full text]
  • Practitioners Guide for Medications in Alcohol and Drug Dependence
    PRACTITIONERS GUIDE FOR MEDICATIONS IN ALCOHOL AND DRUG DEPENDENCE INTRODUCTION It is likely the majority of chemically dependent persons will probably need medications (including both prescriptions and over-the counter) at some point in their recovery. At any time, such medications should only be taken as prescribed by their primary physician in conjunction with their addiction specialist. This Guide is intended to serve as a resource for the recovering chemically dependent person and the medical professional prescribing treatment. It is not meant to be used exclusively or as the sole means for providing advice regarding medications. Indeed, this Guide would be best utilized in conjunction with other concurrent reference materials. Decisions about particular prescription medication(s) should be tailored to the needs of the individual patient under the direction of a health professional. This Guide is not intended to be exhaustive, nor an endorsement of any particular brand name medication. Rather it is intended to provide relevant pharmacological information to the recovering person and health care providers treating those in recovery. GUARDING AGAINST ADDICTION Recovering alcoholics and addicts must be constantly alert to the possibility of triggering a relapse of their disease through the intake of drugs or alcohol. Just as a diabetic needs to be cautious about the intake of sugar, the recovering alcoholic must be sensitive to drugs and the recovering addict must be sensitive to alcohol, and both must be sensitive to other mood-altering drugs, including prescribed and over-the-counter preparations. This Guide is designed to serve as a resource when making decisions regarding what medication(s) to take, as well as a reference tool for those who prescribe medication for persons in recovery.
    [Show full text]
  • Barbiturates
    URINE DRUG TEST INFORMATION SHEET BARBITURATES Classification: Central nervous system depressants insomnia, anxiety or tension due to their very high (CNS Depressants) risk of physical dependence and fatal overdose. Due to the structural nature of barbiturates, the duration Background: Barbiturates are a group of drugs of action does not always correlate well with the that act as central nervous system depressants. biological half-life. Opiates, benzodiazepines and alcohol are also CNS depressants, and like their use, the effect seems to Physiological Effects: Lowered blood pressure, the user as an overall sense of calm. Barbiturates respiratory depression, fatigue, fever, impaired were introduced in 1903, dominating the sedative- coordination, nystagmus, slurred speech and ataxia hypnotic market for the first half of the twentieth century. Unfortunately, because barbiturates have Psychological Effects: Drowsiness, dizziness, unusual a relatively low therapeutic-to-toxic index and excitement, irritability, poor concentration, sedation, substantial potential for abuse, they quickly became confusion, impaired judgment, addiction, euphoria, a major health problem. Barbiturates are commonly decreased anxiety and a loss of inhibition abused for their sedative properties and widespread Toxicity: Barbiturates are especially more availability. The introduction of benzodiazepines in dangerous when abused with alcohol, opiates and the 1960s quickly supplanted the barbiturates due benzodiazepines because they act on the same to their higher safety
    [Show full text]
  • Drugs of Abuse Screens 5,6,9 – Detection Limits
    Drugs of Abuse Screens 5,6,9 – Detection limits Amphetamines low detection limit Benzodiazepines low detection limit d-Amphetamine 1286 ng/mL Alprazolam 65 ng/mL d,I-Amphetamine 2139 ng/mL 7-aminoclonazepam 2600 ng/mL d-Methamphetamine 1000 ng/mL 7-aminoflunitrazepam 590 ng/mL d,I-Methamphetamine 1564 ng/mL Bromazepam 630 ng/mL I-Amphetamine 10407 ng/mL Chlordiazepoxide 3300 ng/mL I-Methamphetamine 2273 ng/mL Clobazam 260 ng/mL Methylenedioxyamphetamine (MDA) 3537 ng/mL Clonazepam 580 ng/mL Methylenedioxymethamphetamine (MDMA) 20538 ng/mL Clotiazepam 380 ng/mL Methylenedioxyethylamphetamine (MDEA) 18230 ng/mL Demoxepam 1600 ng/mL 4-Chloramphetamine 10 µg/mL N-Desalkylflurazepam 130 ng/mL Benzphetamine 1 µg/mL N-Desmethyldiazepam 110 ng/mL Bupropion 1038 µg/mL Diazepam 70 ng/mL Chloroquine 3741 µg/mL Estazolam 90 ng/mL I-Ephedrine 2242 µg/mL Flunitrazepam 140 ng/mL Fenfluramine 105 µg/mL Flurazepam 190 ng/mL Mephentermine 30 µg/mL Halazepam 110 ng/mL Methoxypenamine 331 µg/mL α-Hydroxyalprazolam 100 ng/mL Nor-pseudoephedrine 188 µg/mL 1-N-Hydroxyethylflurazepam 150 ng/mL Phenmetrazine 9 µg/mL α-Hydroxytriazolam 130 ng/mL Phentermine 21 µg/mL Ketazolam 100 ng/mL Phenylpropanolamine (PPA) 133 µg/mL Lorazepam 600 ng/mL Propranolol 386 µg/mL Lormetazepam 200 ng/mL Pseudoephedrine 5889 µg/mL Medazepam 150 ng/mL Quinacrine 8293 µg/mL Midazolam 130 ng/mL Tranylcypromine 126 µg/mL Nitrazepam 320 ng/mL Tyramine 503 µg/mL Norchlordiazepoxide 2600 ng/mL Barbiturates low detection limit Oxazepam 250 ng/mL Allobarbital 345 ng/mL Prazepam 90 ng/mL Alphenal
    [Show full text]
  • Substance Abuse Among Older Adults: an Invisible Epidemic
    1 Substance Abuse Among Older Adults: An Invisible Epidemic ubstance abuse, particularly of alcohol use and misuse of substances, along with a and prescription drugs, among adults 60 reluctance to seek professional help for what S and older is one of the fastest growing many in this age group consider a private health problems facing the country. Yet, even as matter. Many relatives of older individuals with the number of older adults suffering from these substance use disorders, particularly their adult disorders climbs, the situation remains children, are also ashamed of the problem and underestimated, underidentified, choose not to address it. Ageism also contributes underdiagnosed, and undertreated. Until to the problem and to the silence: Younger relatively recently, alcohol and prescription adults often unconsciously assign different drug misuse, which affects up to 17 percent of quality-of-life standards to older adults. Such older adults, was not discussed in either the attitudes are reflected in remarks like, substance abuse or the gerontological literature “Grandmother’s cocktails are the only thing that (D’Archangelo, 1993; Bucholz et al., 1995; makes her happy,” or “What difference does it National Institute on Alcohol Abuse and make; he won’t be around much longer Alcoholism, 1988; Minnis, 1988; Atkinson, 1987, anyway.” There is an unspoken but pervasive 1990). assumption that it’s not worth treating older Because of insufficient knowledge, limited adults for substance use disorders. Behavior research data, and hurried office visits, health considered a problem in younger adults does care providers often overlook substance abuse not inspire the same urgency for care among and misuse among older adults.
    [Show full text]
  • Forensic Toxicology Scope of Testing and Detection Limits
    J. RYAN MCMAHON II County Executive INDU GUPTA, MD, MPH MEDICAL EXAMINER’S OFFICE Commissioner of Health FORENSIC TOXICOLOGY LABORATORY CAROLYN H. REVERCOMB, MD, DABP ONONDAGA COUNTY HEALTH DEPARTMENT Chief Medical Examiner KRISTIE BARBA, MS, D-ABFT-FT CENTER FOR FORENSIC SCIENCES Toxicologist Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES.........................................................................................................2 Volatile Screen by GC/FID .............................................................................................................2 Carbon Monoxide by Microdiffusion..............................................................................................2 Carbon Monoxide by CO-Oximeter ................................................................................................2 Ethylene Glycol by GC/MS.............................................................................................................2 ELISA Buprenorphine by IA for Blood/Urine ................................................................................2 ELISA by IA for Blood ...................................................................................................................3 ELISA by IA for Urine....................................................................................................................4 Gamma Hydroxybutyrate (GHB) by GC/MS..................................................................................5 Gabapentin,
    [Show full text]
  • Laws 2021, LB236, § 4
    LB236 LB236 2021 2021 LEGISLATIVE BILL 236 Approved by the Governor May 26, 2021 Introduced by Brewer, 43; Clements, 2; Erdman, 47; Slama, 1; Lindstrom, 18; Murman, 38; Halloran, 33; Hansen, B., 16; McDonnell, 5; Briese, 41; Lowe, 37; Groene, 42; Sanders, 45; Bostelman, 23; Albrecht, 17; Dorn, 30; Linehan, 39; Friesen, 34; Aguilar, 35; Gragert, 40; Kolterman, 24; Williams, 36; Brandt, 32. A BILL FOR AN ACT relating to law; to amend sections 28-1202 and 69-2436, Reissue Revised Statutes of Nebraska, and sections 28-401 and 28-405, Revised Statutes Cumulative Supplement, 2020; to redefine terms, change drug schedules, and adopt federal drug provisions under the Uniform Controlled Substances Act; to provide an exception to the offense of carrying a concealed weapon as prescribed; to define a term; to change provisions relating to renewal of a permit to carry a concealed handgun; to provide a duty for the Nebraska State Patrol; to eliminate an obsolete provision; to harmonize provisions; and to repeal the original sections. Be it enacted by the people of the State of Nebraska, Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2020, is amended to read: 28-401 As used in the Uniform Controlled Substances Act, unless the context otherwise requires: (1) Administer means to directly apply a controlled substance by injection, inhalation, ingestion, or any other means to the body of a patient or research subject; (2) Agent means an authorized person who acts on behalf of or at the direction of another person but does not include a common or contract carrier, public warehouse keeper, or employee of a carrier or warehouse keeper; (3) Administration means the Drug Enforcement Administration of the United States Department of Justice; (4) Controlled substance means a drug, biological, substance, or immediate precursor in Schedules I through V of section 28-405.
    [Show full text]
  • 201 PART 329—HABIT-FORMING DRUGS Subpart A—Derivatives
    Food and Drug Administration, HHS § 329.1 section 502(e) of the Federal Food, PART 329ÐHABIT-FORMING DRUGS Drug, and Cosmetic Act. (d) The statement expressing the Subpart AÐDerivatives Designated as amount (percentage) of alcohol present Habit Forming in the product shall be in a size reason- ably related to the most prominent Sec. printed matter on the panel or label on 329.1 Habit-forming drugs which are chem- which it appears, and shall be in lines ical derivatives of substances specified in generally parallel to the base on which section 502(d) of the Federal Food, Drug, the package rests as it is designed to be and Cosmetic Act. displayed. (e) For a product to state in its label- Subpart BÐLabeling ing that it is ``alcohol free,'' it must 329.10 Labeling requirements for habit- contain no alcohol (0 percent). forming drugs. (f) For any OTC drug product in- tended for oral ingestion containing Subpart CÐExemptions over 5 percent alcohol and labeled for use by adults and children 12 years of 329.20 Exemption of certain habit-forming age and over, the labeling shall contain drugs from prescription requirements. the following statement in the direc- AUTHORITY: 21 U.S.C. 352, 353, 355, 371. tions section: ``Consult a physician for use in children under 12 years of age.'' SOURCE: 39 FR 11736, Mar. 29, 1974, unless (g) For any OTC drug product in- otherwise noted. tended for oral ingestion containing over 0.5 percent alcohol and labeled for Subpart AÐDerivatives use by children ages 6 to under 12 years Designated as Habit Forming of age, the labeling shall contain the following statement in the directions § 329.1 Habit-forming drugs which are section: ``Consult a physician for use in chemical derivatives of substances children under 6 years of age.'' specified in section 502(d) of the (h) When the direction regarding age Federal Food, Drug, and Cosmetic in paragraph (e) or (f) of this section Act.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • 483 Administrative Records, Texas Department of Criminal Justice
    Consistent with the terms of the Court’s May 22, 2017 scheduling order, the record has been redacted for all information that plaintiff, Texas Department of Criminal Justice (Texas), has identified as confidential. In addition, Defendants have also redacted information that the drug’s supplier and broker have separately advised the agency they consider confidential and private, as well as information the agency itself generally treats as confidential. This information has been redacted pending final FDA’s review of confidentiality claims, and our filing of the record with these redactions does not necessarily reflect our agreement with all of the claims of confidentiality Defendants have received. Defendants explicitly reserve the right to make an independent determination regarding the proper scope of redactions at a later time. Should we identify any of Texas’s redactions that are over-broad or otherwise improper, we will work with Texas’s counsel to revise the redactions in the record. Exhibit 14 FDA 095 Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 1 of 74 CERTJFICATE Pursuant to the provisions ofRule 44 ofthe Federal Rules ofCivil Procedure, I hereby certifY that John Verbeten, Director ofthe Operations and Policy Branch, Division of Import Operations and Policy, Office ofRegional Operations, Office ofRegulatory Affairs, United States Food and Drug Administration, whose declaration is attached, has custody ofofficial records ofthe United States Food and Drug Administration. In witness whereof, I have, pursuant to the provision ofTitle 42, United States Code, Section 3505, and FDA StaffManual Guide 1410.23, hereto set my hand and caused the seal ofthe Department ofHealth and Human Services to be affixed th.is ~oi{.
    [Show full text]
  • Drug Screen Listing
    DRUG SCREEN LISTING The following are detected by a general urine drug screen. Abacavir Acebutolol Acetaminophen Acetohexamide Acyclovir Alprazolam Alprazolam metabolite (alpha-Hydroxyalprazolam) Alprenolol Amantadine Ambroxol Amiloride Amiodarone Amitriptyline Amlodipine Amobarbital as BAR Amoxapine Amphetamine Aprobarbital as BAR Aripiprazole Aripiprazole metabolite (dehydro-aripiprazole) Atenolol Atomoxetine Atorvastatin Atropine Baclofen Barbital as BAR Bendiocarb Benzocaine Benztropine Betaxolol Bisoprolol Bromazepam Bromocriptine Brompheniramine Bupivacaine Buprenorphine Buprenorphine metabolite (norbuprenorphine) Bupropion Buspirone Butabarbital as BAR Butalbital as BAR BZP (1-benzylpiperazine) Caffeine Captopril Carbamazepine Carbamazepine metabolite (10,11-dihydro-10,11- Page 1 of 13 dihydroxycarbamazepine) Carbamazepine metabolite (carbamazepine-10,11-epoxide) Carisoprodol Carvedilol Cathinone Cetirizine Chlordiazepoxide Chlordiazepoxide metabolite (norchlordiazepoxide) Chloroquine Chlorpheniramine Chlorpromazine Chlorpropamide Chlorprothixene Cilazapril Cimetidine Citalopram Citalopram metabolite (desmethylcitalopram) Clenbuterol Clobazam Clobazam metabolite (desmethylclobazam) Clomipramine Clomipramine metabolite (desmethylclomipramine) Clonazepam Clonazepam metabolite (7-Aminoclonazepam) Clonidine Clozapine Clozapine metabolite (clozapine-N-oxide) Clozapine metabolite (norclozapine) Cocaine Cocaine metabolite (benzoylecgonine) Cocaine metabolite (cocaethylene) Cocaine metabolite (ecgoninemethylester) Cocaine metabolite (ethylecgonine)
    [Show full text]
  • Sedative Hypnotics Leon Gussow and Andrea Carlson
    CHAPTER 165 Sedative Hypnotics Leon Gussow and Andrea Carlson BARBITURATES three times therapeutic, the neurogenic, chemical, and hypoxic Perspective respiratory drives are progressively suppressed. Because airway reflexes are not inhibited until general anesthesia is achieved, Barbiturates are discussed in do-it-yourself suicide manuals and laryngospasm can occur at low doses. were implicated in the high-profile deaths of Marilyn Monroe, Therapeutic oral doses of barbiturates produce only mild Jimi Hendrix, Abbie Hoffman, and Margaux Hemingway as well decreases in pulse and blood pressure, similar to sleep. With toxic as in the mass suicide of 39 members of the Heaven’s Gate cult in doses, more significant hypotension occurs from direct depression 1997. Although barbiturates are still useful for seizure disorders, of the myocardium along with pooling of blood in a dilated they rarely are prescribed as sedatives, with the availability of safer venous system. Peripheral vascular resistance is usually normal or alternatives, such as benzodiazepines. Mortality from barbiturate increased, but barbiturates interfere with autonomic reflexes, poisoning declined from approximately 1500 deaths per year in which then do not adequately compensate for the myocardial the 1950s to only two fatalities in 2009.1 depression and decreased venous return. Barbiturates can precipi- Barbiturates are addictive, producing physical dependence and tate severe hypotension in patients whose compensatory reflexes a withdrawal syndrome that can be life-threatening. Whereas tol- are already maximally stimulated, such as those with heart failure erance to the mood-altering effects of barbiturates develops or hypovolemic shock. Barbiturates also decrease cerebral blood rapidly with repeated use, tolerance to the lethal effects develops flow and intracerebral pressure.
    [Show full text]